Vanda Pharmaceuticals Inc
Statements
Cash Flow
Vanda Pharmaceuticals Inc (VNDA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -81 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 | -1.2 | -5.4 | -2.3 | 2.2 | 3.5 | 1.6 | 4.4 | 8.7 | 15 | 9.6 | 21 | 6.0 | 9.8 | -0.9 | 24 | 9.4 | 19 | 9.2 | 19 | 9.4 | 27 | 4.0 | 5.7 | 13 | 9.4 | 32 | -13 | -2.1 | -3.7 | 7.6 | -6.9 | -15 | -1.8 | -33 | -15 | -32 | -29 | -50 | -81 | -193 | |
| 3.2 | 2.4 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | 0.7 | 0.8 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 1.2 | 2.2 | 2.0 | 2.0 | 2.0 | 2.0 | -2.8 | 2.1 | 5.9 | 3.5 | 7.2 | 19 | |
| 2.1 | 2.1 | 2.3 | 2.7 | 2.8 | 2.8 | 3.2 | 2.7 | 2.9 | 2.9 | 3.3 | 3.1 | 3.4 | 3.7 | 3.9 | 3.1 | 3.1 | 3.2 | 3.9 | 3.7 | 4.0 | 3.8 | 4.8 | 3.8 | 3.9 | 3.8 | 4.4 | 3.2 | 3.2 | 3.3 | 3.6 | 3.0 | 3.0 | 2.9 | 3.0 | 2.1 | 2.1 | 2.3 | 2.6 | 4.7 | 12 | |
| 2.6 | 2.2 | 2.4 | 2.7 | 3.0 | 3.0 | 3.0 | 2.9 | 2.9 | 2.9 | 3.6 | 3.5 | -85 | 5.3 | 5.1 | 4.6 | 5.6 | 6.0 | 5.4 | 6.4 | 7.0 | 5.6 | 9.7 | 2.4 | 2.7 | 5.0 | 7.5 | 5.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -4.1 | -5.1 | -0.8 | -4.1 | 3.1 | 1.7 | -5.0 | -3.5 | -1.4 | 2.1 | 6.9 | 5.7 | -9.4 | 0.0 | -7.0 | 10 | -3.1 | 4.0 | -6.0 | 2.3 | -6.6 | 13 | -0.1 | 0.1 | 7.4 | -1.3 | 22 | -19 | -6.8 | 2.8 | 7.0 | -4.6 | -9.6 | 0.7 | -1.9 | 15 | -8.1 | 3.0 | -7.9 | 17 | 4.3 | |
| 0.6 | 0.7 | 0.5 | 0.6 | 0.4 | 0.2 | 0.1 | 25 | 0.1 | 0.0 | 0.4 | 0.3 | 0.3 | 0.1 | 0.4 | 0.2 | 0.2 | 1.0 | 0.1 | 0.3 | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.1 | 0.1 | 0.0 | 0.3 | 0.0 | 0.1 | 0.2 | 0.2 | 0.4 | 0.3 | 0.2 | 0.1 | 0.2 | 0.4 | 0.9 | |
| 2.4 | 8.1 | -17 | -5.8 | 5.4 | 7.5 | 16 | -101 | -8.9 | -16 | -36 | -12 | -14 | -6.2 | 20 | 2.7 | -48 | -17 | 0.1 | -34 | -17 | -26 | 11 | -15 | -22 | 75 | 187 | -191 | 35 | -44 | -18 | -15 | 12 | 4.0 | 44 | -15 | 21 | 45 | 20 | 54 | 141 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 6.0 | 0.8 | 2.2 | 2.2 | 0.8 | 0.1 | 104 | 2.5 | 0.1 | 0.8 | 0.2 | 3.4 | 0.6 | 2.1 | 0.5 | 3.6 | 0.1 | 1.4 | 1.8 | 0.3 | 0.4 | 1.0 | – | 0.1 | 0.0 | 0.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.4 | -0.4 | -0.5 | -0.6 | -0.8 | -0.9 | -2.8 | |
| 6.0 | 0.8 | 2.2 | 2.2 | 0.8 | 0.1 | 104 | 2.5 | 0.1 | 0.8 | 0.2 | 3.4 | 0.6 | 2.1 | 0.5 | 3.6 | 0.1 | 1.4 | 1.8 | 0.3 | 0.4 | 1.0 | 0.1 | 0.1 | 0.0 | 0.6 | – | – | 0.0 | 0.0 | 0.0 | 0.0 | – | -0.2 | -1.3 | -0.4 | -0.5 | -0.6 | -0.8 | -1.6 | -3.6 | |
| 9.6 | 7.7 | -20 | -5.9 | 8.4 | 11 | 122 | -94 | -0.1 | 0.2 | -27 | 12 | -7.3 | 5.7 | 20 | 30 | -38 | 4.1 | 11 | -15 | -6.8 | 1.5 | 15 | -8.7 | -8.8 | 86 | 219 | -204 | 33 | -47 | -11 | -22 | -2.5 | 1.8 | 9.5 | -31 | -11 | 15 | -31 | -29 | -56 | |
| 0.6 | -1.9 | -5.8 | -2.9 | 1.8 | 3.3 | 1.5 | -21 | 8.6 | 15 | 9.3 | 20 | 5.7 | 9.7 | -1.3 | 24 | 9.1 | 18 | 9.1 | 19 | 9.4 | 26 | 4.0 | 5.5 | 13 | 9.2 | 32 | -13 | -2.1 | -4.0 | 7.6 | -7.0 | -15 | -2.0 | -34 | -16 | -32 | -30 | -50 | -82 | -193 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.